Literature DB >> 1735366

PAF-acether and acetylhydrolase in stool of patients with Crohn's disease.

Y Denizot1, S Chaussade, N Nathan, J F Colombel, M J Bossant, N Cherouki, J Benveniste, D Couturier.   

Abstract

PAF-acether (PAF) is a phospholipid mediator with potent biological effects on the digestive tract. We report the presence of PAF in stool of patients with active Crohn's disease (39.1 +/- 13.5 ng/g of stool, mean +/- SEM, N = 19) and its absence in patients with irritable bowel syndrome with diarrhea and diarrhea with malabsorption. Fecal PAF acetylhydrolase activity was higher (P less than 0.04) in patients with Crohn's disease as compared to patients with irritable bowel syndrome with diarrhea and diarrhea with malabsorption. We also report a solid-phase extraction of fecal PAF using silica minicolumns, which yielded results highly correlated with those obtained with a high-performance liquid chromatography method (r = 0.86, P less than 0.001, N = 16). These findings may allow us to implicate PAF in the onset and perpetuation of digestive tract inflammatory symptoms observed during Crohn's disease. They would warrant to investigate the influence of various therapeutic agents, including PAF antagonists, on fecal PAF levels during inflammatory digestive ailments.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1735366     DOI: 10.1007/bf01307739

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  23 in total

1.  Presence of PAF-acether in stool of patients with infectious diarrhea.

Authors:  Y Denizot; S Chaussade; J Benveniste; D Couturier
Journal:  J Infect Dis       Date:  1991-05       Impact factor: 5.226

2.  Structural analysis of purified platelet-activating factor by lipases.

Authors:  J Benveniste; J P Le Couedic; J Polonsky; M Tence
Journal:  Nature       Date:  1977-09-08       Impact factor: 49.962

3.  Hypoxia causes ischemic bowel necrosis in rats: the role of platelet-activating factor (PAF-acether).

Authors:  M S Caplan; X M Sun; W Hsueh
Journal:  Gastroenterology       Date:  1990-10       Impact factor: 22.682

4.  Solid-phase extraction on silica cartridges as an aid to platelet-activating factor enrichment and analysis.

Authors:  D R Janero; C Burghardt
Journal:  J Chromatogr       Date:  1990-03-16

5.  Novel aspect of Crohn's disease: increased content of platelet-activating factor in ileal and colonic mucosa.

Authors:  B Kald; G Olaison; R Sjödahl; C Tagesson
Journal:  Digestion       Date:  1990       Impact factor: 3.216

6.  Potent ulcerogenic actions of platelet-activating factor on the stomach.

Authors:  A C Rosam; J L Wallace; B J Whittle
Journal:  Nature       Date:  1986 Jan 2-8       Impact factor: 49.962

7.  BN 52021 displaces [3H]paf-acether from, and inhibits its binding to intact human platelets.

Authors:  R Korth; J Benveniste
Journal:  Eur J Pharmacol       Date:  1987-10-27       Impact factor: 4.432

8.  Release, purification, and characterization of platelet-activating factor (PAF).

Authors:  V Tencé; J Polonsky; J P Le Couedic; M J Benveniste
Journal:  Biochimie       Date:  1980       Impact factor: 4.079

9.  Increased phospholipase A2 activity of Ileal mucosa in Crohn's disease.

Authors:  G Olaison; R Sjödahl; C Tagesson
Journal:  Digestion       Date:  1988       Impact factor: 3.216

10.  Synthesis of paf-acether from exogenous precursors by the prokaryote Escherichia coli.

Authors:  Y Denizot; E Dassa; H Y Kim; M J Bossant; N Salem; Y Thomas; J Benveniste
Journal:  FEBS Lett       Date:  1989-01-16       Impact factor: 4.124

View more
  14 in total

1.  Correlation of desensitisation of platelet activating factor (PAF) receptors with intensity of inflammation and intestinal PAF content during experimental ileitis in guinea pig.

Authors:  O Jeanneton; M Delvaux; Y Langlois; P Le Bars; J Le Bars; M B Delisle; J Frexinos; L Bueno
Journal:  Gut       Date:  1998-09       Impact factor: 23.059

2.  Quantification of distinct molecular species of platelet activating factor in ulcerative colitis.

Authors:  E Thyssen; J Turk; A Bohrer; W F Stenson
Journal:  Lipids       Date:  1996-03       Impact factor: 1.880

Review 3.  Structural and (patho)physiological diversity of PAF.

Authors:  R N Pinckard; D S Woodard; H J Showell; M J Conklyn; M J Novak; L M McManus
Journal:  Clin Rev Allergy       Date:  1994

Review 4.  Metabolic processing of PAF.

Authors:  F Snyder
Journal:  Clin Rev Allergy       Date:  1994

Review 5.  Platelet-activating factor antagonists.

Authors:  M Koltai; P G Braquet
Journal:  Clin Rev Allergy       Date:  1994

6.  Platelet activating factor and Crohn's disease.

Authors:  Y Denizot; S Chaussade
Journal:  Gut       Date:  1994-01       Impact factor: 23.059

Review 7.  Key role of mast cells and their major secretory products in inflammatory bowel disease.

Authors:  Shao-Heng He
Journal:  World J Gastroenterol       Date:  2004-02-01       Impact factor: 5.742

8.  Treatment of Crohn's disease recurrence after ileoanal anastomosis by azathioprine.

Authors:  W Berrebi; S Chaussade; A L Bruhl; A Pariente; P Valleur; P Hautefeuille; D Couturier
Journal:  Dig Dis Sci       Date:  1993-08       Impact factor: 3.199

9.  Platelet-activating factor-induced chloride channel activation is associated with intracellular acidosis and apoptosis of intestinal epithelial cells.

Authors:  Erika C Claud; Jing Lu; Xue Qing Wang; Mark Abe; Elaine O Petrof; Jun Sun; Deborah J Nelson; Jeremy Marks; Tamas Jilling
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-03-13       Impact factor: 4.052

10.  Intraluminal excretion of PAF, lysoPAF, and acetylhydrolase in patients with ulcerative colitis.

Authors:  R Guimbaud; A Izzo; J P Martinolle; N Vidon; D Couturier; J Benveniste; S Chaussade
Journal:  Dig Dis Sci       Date:  1995-12       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.